Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 24, 2025The OncologistOpen Access

Exploring the Impact of first-line Durvalumab plus chemotherapy on advanced biliary tract cancer: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPatrick ReimannESEva-Maria SchneiderADAngela Djanani

Discussion

Loading...

Member takes

Overview

Systematic review highlights improved overall survival and progression free survival in advanced biliary tract cancer patients treated with durvalumab plus chemotherapy, indicating its effectiveness.

Key Points

  • Main finding shows durvalumab plus gemcitabine/cisplatin improves overall survival in advanced biliary tract cancer.
  • Meta-analysis of 10 trials with 2877 patients demonstrated statistically significant survival benefits.
  • Rigorous trial selection and quality assessment methods ensured credible evidence was included in the analysis.
  • Findings underline durvalumab plus chemotherapy as the current best treatment option, yet stress the need for more real-world data.

Cite This Study

Reimann et al. (2025) studied this question.

synapsesocial.com/papers/689a0621e6551bb0af8cdebdhttps://doi.org/10.1093/oncolo/oyaf224
View Full Paper
Ask AI
Bookmark
Share